Dalfampridine: is the seizure risk greater than previously thought?
Department of PM&R, UMDNJ-New Jersey Medical School, Newark, NJ, USA.
Amanda
A
Farag
Allison
A
Averill
D015761:4-Aminopyridine / Q000009:adverse effects* / Q000627:therapeutic use; D000077265:Donepezil; D005500:Follow-Up Studies; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use; D026902:Potassium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects*; D018570:Risk Assessment; D012640:Seizures / Q000139:chemically induced* / Q000503:physiopathology; D012720:Severity of Illness Index
D007189:Indans; D010880:Piperidines; D026902:Potassium Channel Blockers; D000077265:Donepezil; D015761:4-Aminopyridine